David J Monsma
Overview
Explore the profile of David J Monsma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgenske D, Monsma D, MacKeigan J
Methods Mol Biol
. 2018 Mar;
1765:307-314.
PMID: 29589317
Preclinical compounds tested in animal models often demonstrate limited efficacy when transitioned into patients. As a result, individuals are assigned to treatment regimens that may be ineffective at treating their...
2.
Monsma D, Cherba D, Eugster E, Dylewski D, Davidson P, Peterson C, et al.
Am J Cancer Res
. 2015 Jun;
5(4):1507-18.
PMID: 26101714
Variable clinical responses, tumor heterogeneity, and drug resistance reduce long-term survival outcomes for metastatic melanoma patients. To guide and accelerate drug development, we characterized tumor responses for five melanoma patient...
3.
Foley J, Scholten 2nd D, Monks N, Cherba D, Monsma D, Davidson P, et al.
J Transl Med
. 2015 Apr;
13:110.
PMID: 25889105
Background: Osteosarcoma (OS) is the most common type of solid bone cancer, with latent metastasis being a typical mode of disease progression and a major contributor to poor prognosis. For...
4.
Burgenske D, Monsma D, Dylewski D, Scott S, Sayfie A, Kim D, et al.
Am J Cancer Res
. 2014 Dec;
4(6):824-37.
PMID: 25520871
Preclinical compounds tested in animal models often show limited efficacy when transitioned into human clinical trials. As a result, many patients are stratified into treatment regimens that have little impact...
5.
Monsma D, Cherba D, Richardson P, Vance S, Rangarajan S, Dylewski D, et al.
Pediatr Blood Cancer
. 2014 Apr;
61(9):1570-7.
PMID: 24687871
Background: Precision (Personalized) medicine has the potential to revolutionize patient health care especially for many cancers where the fundamental disease etiology remains either elusive or has no available therapy. Here...
6.
Monsma D, Monks N, Cherba D, Dylewski D, Eugster E, Jahn H, et al.
J Transl Med
. 2012 Jun;
10:125.
PMID: 22709571
Background: There is resurgence within drug and biomarker development communities for the use of primary tumorgraft models as improved predictors of patient tumor response to novel therapeutic strategies. Despite perceived...
7.
Kuick R, Misek D, Monsma D, Webb C, Wang H, Peterson K, et al.
Cancer Lett
. 2007 Feb;
249(1):40-8.
PMID: 17320282
Although our understanding of the molecular pathogenesis of common types of cancer has improved considerably, the development of effective strategies for cancer diagnosis and treatment have lagged behind. Mouse models...
8.
Creighton C, Bromberg-White J, Misek D, Monsma D, Brichory F, Kuick R, et al.
Mol Cancer Res
. 2005 Mar;
3(3):119-29.
PMID: 15798092
Tumor cell lines are relied on extensively for cancer investigations, yet cultured cells in an in vitro environment differ considerably in behavior compared with those of the same cancer cells...